How heart cells contribute to heart problems caused by Doxorubicin chemotherapy
Official title: Cardiac fibroblast MHCII contribution to cardiac pathophysiology in Doxorubicin cardiomyopathy
Funded at Tufts University Boston · NIH-10994472 · Data updated 2026-11-12
This study is looking at how certain heart cells called cardiac fibroblasts might cause heart problems in cancer patients who have been treated with Doxorubicin, with the hope of finding ways to protect their hearts from damage.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $45,162 |
| NIH project number | 1F31HL175911-01 |
| Project ID | NIH-10994472 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are undergoing treatment with Doxorubicin and are at risk of developing heart complications.
✕Less likely to help
Patients who have not received Doxorubicin or those with pre-existing heart conditions unrelated to chemotherapy may not benefit from this research.
What this research studies
This research investigates how cardiac fibroblasts, a type of heart cell, contribute to heart issues in patients who have received Doxorubicin chemotherapy. The study focuses on understanding the role of these cells in inflammation and fibrosis, which are common complications leading to heart failure. By using a mouse model, researchers will explore how these fibroblasts interact with immune cells and how their behavior changes in response to Doxorubicin. The goal is to identify mechanisms that could potentially be targeted to prevent heart damage in cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing heart failure in cancer patients treated with Doxorubicin.
How similar studies have gone: Previous research has shown that targeting immune responses in heart disease can be beneficial, suggesting that this approach may also yield positive results.
Where this research is happening
-
Tufts University Boston
Boston, United States Active
Researchers
- Principal investigator: Zambrano, Maria Antonia — Tufts University Boston
- Study coordinator: Zambrano, Maria Antonia
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.